Latest News
JAC Recruitment H1 FY2026 Earnings Deep Dive: Dominance in High-Income/Professional Talent and Aggressive Capital Allocation
Introduction JAC Recruitment Co., Ltd. (TSE: 2124) reported record-high levels
Yagami (7488) Latest Earnings: Operating Income Decreases 8.2% YoY to 426 Million Yen
Yagami (7488) has released its latest financial results, reporting operating income of 426 million yen, which is a decrease of 8.2% compared to the same period of the previous year. Net sales stood at
Fibergate FY2026 Full-Year Financial Results: Business Structural Transformation and New Strategies for Renewed Growth
1. FY2026 Consolidated Financial Highlights and Variance Analysis Fibergate Inc. rep
AeroEdge FY2026 Earnings Deep Dive: Record-Breaking Performance Driven by Blade Production Ramp-up and M&A, Growth Accelerating to ¥7.95 Billion in FY2027
1. Earnings Highlights and Executive Summary AeroEdge (TSE Growth: 7409) delivered a
Serendip Holdings: Q1 FY2027 Earnings & 'Challenge 1000' Mid-Term Management Plan Deep Dive
Serendip Holdings: Q1 FY2027 Earnings & Mid-to-Long-Term Growth Strategy Deep Dive Se
TeraProbe (6627) Q2 FY2026 Earnings Deep Dive: High-Growth Trajectory Driven by Advanced Data Center Demand and New Taiwan Facility
1. Q2 FY2026 Earnings Overview TeraProbe, Inc. (6627) delivered strong growth in the
ヒューマン・メタボローム・テクノロジーズ 2026年6月期決算と新5か年中期経営計画「TIAD-6」の全貌
ヒューマン・メタボローム・テクノロジーズ株式会社（HMT）の2026年6月期決算および、新たに策定された5か年中期経営計画「TIAD-6（2026年7月〜2031年6月）」
Toyo Tanso FY2026 H1 Earnings Deep Dive: Semiconductor Inventory Adjustments, H2 Recovery Scenarios, and Growth Investment Status
1. FY2026 H1 Earnings Highlights Toyo Tanso’s consolidated financial results for the
eWeLL (5038) H1 FY2026 Earnings Analysis: Sustained High-Profitability, Accelerated AI Monetization, and a New Growth Phase Driven by 108% NRR
1. H1 FY2026 Earnings Highlights eWeLL Co., Ltd. (5038) achieved significant growth
Waqoo (4937) Q3 FY2026 Earnings Deep Dive: Business Transformation Yields Second Upward Revision, Operating Profit Surges 3.7x YoY to ¥560 Million
1. Executive Summary: Completion of Strategic Pivot from D2C to Medical Support for R
Takemoto Yohki Q2 FY2026 Earnings Deep Dive: Profitability Growth Driven by Sustainable Packaging Expansion and Global Development
1. Q2 FY2026 Consolidated Financial Highlights For the first half of the fiscal year
Sharing Innovations Q2 FY2026 Earnings Analysis: Profitability Structure Improves During 'Recovery Phase' with 207% YoY Operating Profit Growth; AI-Driven Transformation and H2 Outlook
Sharing Innovations' financial results for the second quarter of the fiscal year ending
[G-FACTORY FY12/2026 Q2] A Turning Point in Profit Structure Driven by Structural Reform and Overseas Growth: The Full Scope of the Restaurant Platform Strategy via the 'Omise Craft' Acquisition
Introduction: A Transitional Phase Balancing Structural Reform and Growth Investment
JINUSHI Co., Ltd. (3252) Q2 FY2026 Earnings Deep Dive: Accelerating Acquisitions with Interest Rate and Inflation Resilience, Setting a Solid Foundation for Full-Year Targets
1. Overview of Q2 FY2026 Financial Results and Revenue Structure JINUSHI Co., Ltd. (
Temairazu (2477) FY2026 Earnings Analysis: Growth Strategy Driven by High-Margin SaaS Evolution and Robust Inbound Demand
1. FY2026 Earnings Summary: Record-High Revenue and Profit Temairazu, Inc. reported
[L is B] Q2 FY2026 Earnings Q&A Deep Dive: Unlocking the Next Growth Phase through Price Optimization and 'Field-Specialized AI'
L is B Co., Ltd. (Securities Code: 145A) is a SaaS company driving digital transformatio
Yamano Holdings Q1 FY2027 Earnings Analysis: Progress in Portfolio Transformation and Strengthening of Revenue Base through M&A Strategy
Yamano Holdings Corporation (TSE Standard: 7571) has announced its financial results for
ポート(7047) 2027年3月期 第1四半期 決算説明会Q&A分析：ストック型収益構造への転換と人材領域の急成長が示す中長期戦略
ポート株式会社（証券コード: 7047）の2027年3月期第1四半期決算説明会における主な質疑応答（Q&A）の内容を基に、同社の事業進捗、構造改革、中長期的な成長シナリオについ
K Pharma FY2026 H1 Earnings Deep Dive: Clinical Progress and Commercialization Strategy for iPS Drug Discovery and Regenerative Medicine Pipelines
K Pharma Inc. (4896), a biotech venture originating from Keio University, has released i
Kubota Pharmaceutical Holdings Q2 FY2026 Earnings Deep Dive: Advancing Pipeline Commercialization and European CUP Strategy Through Intellectual Property Leverage
Executive Summary In the second quarter (interim period) of the fiscal year ending D